Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
If you are among the people in America who agree with one or other of the following two statements, you need an immediate crash course in what approval of a new drug by the U.S. Food & Drug Administration (FDA) does actually mean:
Filed under: Drugs in development, Management, Treatment | Tagged: approval, benefit, FDA, risk | 9 Comments »
There is an interesting article on Kaiser Health News today discussing the risks associated with “over-testing” of elderly and sometimes very infirm people who are at relatively low risk for specific chronic diseases, including prostate cancer.
Filed under: Diagnosis, Risk | Tagged: aging, life expectancy, mortality, over-testing, risk, screening | 7 Comments »
Dr. Gerry Chodak is the author of Winning the Battle Against Prostate Cancer, the creator of the ProstateVideos.com web site, and the founder of the Chicago-based patient support group that became the basis for Us TOO International.
Filed under: Uncategorized | Leave a Comment »
Initially, androgen deprivation therapy (ADT) was conceived of and developed as long-term, palliative therapy for men with evident and commonly painful forms of metastatic prostate cancer. The primary goal was the alleviation of pain associated with metastasis, and had little or nothing to do with the patient’s long-term survival.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, internittent, therapy | 2 Comments »
Every day across America and around the world, newly diagnosed patients are told they have “localized” prostate cancer … with the associated implication that this is a relatively “good thing” compared to a diagnosis of “advanced” prostate cancer. But what does “localized” prostate cancer really mean in individual cases?
Filed under: Diagnosis, Management, Risk | Tagged: category, definition, localized, sub-category | 4 Comments »
According to a media release issued by the Canadian company BioCurex earlier today, its new RECAF™ test “outperformed the established free-PSA test by approximately 600% in its ability to prevent unnecessary prostate biopsies.”
Filed under: Diagnosis, Risk | Tagged: BioCurex, biopsy, α-fetoprotein, RECAF, test | Leave a Comment »
Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, approval, Europe | Leave a Comment »
The association of depression with a diagnosis of and subsequent treatment for prostate cancer is well appreciated, but the prevalence of that depression and the burden it places on men with prostate cancer over time has been less well documented.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: depression, mortality, outcome, risk | 5 Comments »
The August 15 issue of American Family Physician — supposedly one of the most widely read medical journals in America — carried an article by Mohan and Schellhammer entitled “Treatment options for localized prostate cancer.” Unfortunately the full text of this article is not available on line for the average reader.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: doctor, eductation, family, Management, physician, update | 4 Comments »
It is well understood that there can be big differences between what we are told and what we later say and think that we heard. It is also the case that what we are told may commonly reflect the beliefs of the person doing the telling (as opposed to actual, factual information).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: decision, expectation, perspective, selection, Treatment | 7 Comments »
Over the years there have been many reports associating intake of cruciferous vegetables, tomato sauce, and legumes with a reduction in risk for advanced prostate cancer. However, definitive clinical data are still few and far between.
Filed under: Uncategorized | 9 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site